Intravascular studies with iohexol (Omnipaque). Results from the first 49 clinical trials.
In order to assess the vascular clinical trial program of iohexol (Omnipaque) in Europe, the results from the first 49 vascular trials are collectively reported. The included iohexol material comprises 1742 patients. In 40 comparative trials, other contrast media like metrizamide (Amipaque), ioxaglate (Hexabrix) and various monomeric ionic media were administered in 1292 patients included in this analysis. No severe or unexpected adverse reactions related to iohexol were encountered. No clinically significant differences in radiographic image quality between the media were documented. The overall tolerability of iohexol was superior to that of monomeric ionic media and seemed to be as good as that of metrizamide.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000790:Angiocardiography; D000792:Angiography; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007223:Infant; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D007463:Iodobenzoates / Q000008:administration & dosage*; D007472:Iohexol; D008297:Male; D008875:Middle Aged; D010690:Phlebography; D014055:Tomography, Emission-Computed; D014283:Triiodobenzoic Acids / Q000008:administration & dosage* / Q000009:adverse effects; D014567:Urography
D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol